NeoVentures Debuts at MEDICA -- MEDICA - World Forum for Medicine


NeoVentures Biotechnology Inc.

NeoVentures Debuts at MEDICA


LONDON, Ontario, Oct. 30, 2013 – NeoVentures Biotechnology Inc. will make its first appearance at  MEDICA, the world's largest annual medical trade fair, Nov. 20-23 in Düsseldorf, Germany – showcasing their aptamer development platform that could transform if not revolutionize diagnostic testing by reducing costs, increasing test sensitivity, and speeding development time to market.


“We’re the first company globally to bring an aptamer-based diagnostic kit to market,” says NeoVentures President and CEO, Gregory Penner, PhD. “But a lot of people in healthcare are either unaware of aptamers or think that they do not work. We are coming to MEDICA to show the world that they do indeed work – very well for us and also for our clients.”


At MEDICA 2013, Dr. Penner and his ten-year-old company will be demonstrating their existing aptamer-based products and describing how they can be customized for use in a broad range of diagnostics.


“Aptamers are DNA-based  ligands (chemical molecules that bind specifically to target molecules) that have the potential to become a truly disruptive technology and replace antibodies currently used in diagnostic testing,” explains Penner. “But just as DVDs did to existing recording industry with their benign disruption, aptamers have the same potential to change the diagnostic market – without fundamentally changing the process of diagnostic testing. It will still be familiar to all users, just as DVDs were immediately familiar to music and movie lovers.”


Considering the potentially vast range of aptamer applications in diagnostics, Penner and NeoVentures have taken an unusual, non-proprietary approach to commercializing their aptamer technology and skills.


“We have built on our real-world experience over the past ten years to establish a world-wide aptamer development service with a simple, business-friendly package,” says Penner. “In simple terms, the clients tells us what diagnostic test they want developed. We then go to work, normally analyzing over 20 million possible aptamers and then thoroughly testing what our calculations reveal to be the best bets. Usually this takes about four months of collaborative work with the client, and then we hand over the best aptamers to the client with no strings attached. They are free to use it how they want and to develop whatever else they want to with it.”


Penner and NeoVentures will be describing their cutting edge aptamer discovery and validation process to visitors at MEDICA in Hall 3, booth H14, part of the Canada/Ontario pavilion with the red maple leaf on top.    


For more information on NeoVentures in the meantime, please visit our website or contact us at 1 519 858 5052 by telephone or info@neoventures by email. Also, you can search for us in “Companies & Products” on the website.